Cybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Cybin in a research note issued on Friday, August 23rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Cybin's current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Cybin's Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS and FY2028 earnings at $0.11 EPS.
Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Cybin in a report on Wednesday, July 31st.
Read Our Latest Report on Cybin
Cybin Stock Performance
Shares of NYSE CYBN remained flat at $0.27 during mid-day trading on Monday. The company had a trading volume of 4,083,561 shares, compared to its average volume of 4,739,461. Cybin has a 1-year low of $0.24 and a 1-year high of $0.74. The firm has a market cap of $109.29 million, a price-to-earnings ratio of -1.33 and a beta of 0.43. The business's 50 day simple moving average is $0.27.
Cybin (NYSE:CYBN - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share for the quarter.
Institutional Investors Weigh In On Cybin
Institutional investors and hedge funds have recently modified their holdings of the stock. PEAK6 Investments LLC acquired a new stake in shares of Cybin during the 1st quarter valued at $95,000. AdvisorShares Investments LLC boosted its position in Cybin by 13.4% during the second quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company's stock valued at $494,000 after purchasing an additional 220,403 shares during the last quarter. AWM Investment Company Inc. purchased a new position in Cybin in the first quarter valued at about $930,000. Rosalind Advisors Inc. raised its stake in shares of Cybin by 38.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company's stock worth $5,230,000 after purchasing an additional 5,340,000 shares in the last quarter. Finally, Ikarian Capital LLC acquired a new stake in shares of Cybin during the 1st quarter valued at about $5,770,000. Institutional investors and hedge funds own 17.94% of the company's stock.
Cybin Company Profile
(
Get Free Report)
Cybin Inc is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc is based in Toronto, Canada.
Read More
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
